Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

2.70
+0.07002.66%
Volume:541.09K
Turnover:1.44M
Market Cap:526.50M
PE:-10.65
High:2.73
Open:2.69
Low:2.64
Close:2.63
52wk High:3.11
52wk Low:1.12
Shares:195.00M
Float Shares:163.00M
Volume Ratio:0.54
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2535
EPS(LYR):-0.2325
ROE:-25.96%
ROA:-23.46%
PB:2.51
PE(LYR):-11.61

Loading ...

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)

TIPRANKS
·
Jun 09

Ovid Therapeutics to present at Oppenheimer CNS & Neuro-Muscular Summit

Reuters
·
Jun 04

Ovid Therapeutics names Anna Greka to board of directors

Reuters
·
Jun 03

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.d., Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 03

Press Release: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Dow Jones
·
Jun 03

LifeSci Capital Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
May 16

B. Riley Securities Keeps Their Buy Rating on Ovid Therapeutics (OVID)

TIPRANKS
·
May 13

Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)

TIPRANKS
·
May 13

Ovid Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Ovid Therapeutics Q1 net loss widens as R&D spending rises

Reuters
·
May 12

Ovid Therapeutics releases corporate presentation on neural hyperexcitability drug pipeline

Reuters
·
May 12

Ovid Therapeutics Q1 Operating Expenses USD 17.846 Million

THOMSON REUTERS
·
May 12

Ovid Therapeutics Q1 EPS USD -0.12

THOMSON REUTERS
·
May 12

Ovid Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 08

Ovid Therapeutics says Series A warrants expire after $53.9 million exercise

Reuters
·
Apr 20

Ovid Therapeutics (OVID) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Apr 20

Ovid Therapeutics to host KCC2 deep-dive R&D event on first-in-class activators

Reuters
·
Apr 08

Ovid Therapeutics (OVID) Gets a Buy from Wedbush

TIPRANKS
·
Apr 07

LifeSci Capital Sticks to Their Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Mar 28

Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Ovid Therapeutics (OVID)

TIPRANKS
·
Mar 24